Pneumocystis Pneumonia
Conditions
Keywords
Caspofungin, corticosteroids, Pneumocystis Pneumonia, Immunocompromised, Non-HIV, respiratory failure
Brief summary
Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The effects and safety of caspofungin and corticosteroids is not certain in this population. All Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28 day mortality, the second outcome are time of respiratory rate decreases to less than 25 breath per minute, body temperature lower than 37.3℃.
Interventions
DRUGcaspofungin
70mg ivdrip the first day, then 50mg ivdrip qd
DRUGcorticosteroids
40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
DRUGSulfanilamides
1.92g q8h
Sponsors
Beijing Chao Yang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Immunocompromised Non-HIV Infected Patients * Partial arterial O2 pressure(PaO2)/FiO2≤300mmHg * Diagnosed as Pneumocystis Pneumonia
Exclusion criteria
* younger than 16 years old * severe organ failure * allergic to sulfanilamide, caspofungin or corticosteroid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mortality | 28 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time for release of fever | 2 days | Time for body temperature less than 37.3℃ for 48 hours |
| Time for release of respiratory distress | 2 days | Time for respiratory rate \<25 breathes per minute for 48 hours |
Countries
China
Contacts
Primary ContactHangyong He, MM
Outcome results
None listed